Aldeyra Therapeutics to Advance ADX-1612, an Investigational New HSP90 Inhibitor with Potential Nanomolar Potency Against SARS-CoV-2, to Clinical Testing for COVID-19; ADX-629 Accepted for BA
May 20, 2020
- ADX-1612 Demonstrates Nanomolar SARS-CoV-2 Antiviral Potency In Vitro
- Pending FDA Feedback, IND Submission for ADX-1612 Expected in Third Quarter 2020
- IND Submission for ADX-629 Expected in?June 2020
- Management to Host Conference Call at?8:00 a.m. ET?Today
1?HSP90: a promising broad-spectrum antiviral drug target.?Arch Virol. 2017; 162(11): 3269-3282; Could targeting the heat shock protein 90 revolutionize antiviral therapy??Future Virology?2018; 13(2): 119-127. |
2?Bulk and single-cell gene expression profiling of SARS-CoV-2 infected human cell lines identifies molecular targets for therapeutic intervention.?BioRxiv2020.?https://doi.org/10.1101/2020.05.05.079194. |
View source version on?businesswire.com:?https://www.businesswire.com/news/home/20200520005228/en/
Corporate:? David McMullin Aldeyra Therapeutics, Inc. Tel: 781-761-4904 ext. 218 dmcmullin@aldeyra.com Investor & Media:? Scott Solomon Sharon Merrill Associates, Inc. Tel: 617-542-5300 ALDX@investorrelations.com Source:?Aldeyra Therapeutics, Inc.